June 27, 2017 / 11:22 AM / 24 days ago

BRIEF-Alder Biopharmaceuticals announces positive eptinezumab phase 3 results

1 Min Read

June 27 (Reuters) - Alder Biopharmaceuticals Inc

* Alder Biopharmaceuticals announces positive eptinezumab phase 3 results for prevention of frequent episodic migraine

* Says ‍​pivotal promise 1 top-line results show eptinezumab met primary and key secondary endpoints

* Says beginning day 1 after first dose, significant reduction in proportion of patients experiencing migraine

* Says average of 1 in 5 patients had no migraines in any given month over months 1 through 6

* Says Promise 1 met the primary endpoint, that is highly statistically significant reductions in monthly migraine days

* enrollment is on track for Promise 2; remains on track to submit BLA with FDA in second half of 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below